Co-Occurring Psychiatric and Substance Use Disorders: Clinical Survey Among a Rural Cohort of Italian Patients

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2020 Jan 8

PMID 31908460

Citations 4

Authors

Giulia Milano

Hayley M Vergani

Simone Cattedra

Roberto Carrozzino

Francesca Mattioli

Luigi Robbiano

Antonietta Martelli

Affiliations

Soon will be listed here.

Abstract

Purpose: Dual diagnosis (DD) is the co-occurrence of both a mental illness and a substance use disorder (SUD). Lots of studies have analysed the integrated clinical approach, which involves both psychiatry and toxicology medical experts. The purpose of this study is to analyse the socio-demographic characteristics and treatment strategies of patients with DD in a rural area of Italy.

Patients And Methods: Clinical data of 750 patients were collected in 2016 through the analysis of health plan records.

Results: The rate of co-occurring disorders is highly variable among people with SUD. In the considered area, patients with DD are 24%, of these only 46.1% have been treated with an integrated clinical program. Moreover, this percentage is further reduced (35.8%) if only patients with heroin use disorder are considered.

Conclusion: A comprehensive revision of DD treatment is needed, especially for people suffering from heroin use disorder and living in remote areas. Meticulous data analysis from other addiction health services of rural areas could be necessary to identify a science-based clinical intervention.

Citing Articles

Perceived Higher Unmet Care Needs among Adults in Permanent Supportive Housing.

Armoon B, Grenier G, Fleury M Adm Policy Ment Health. 2024; 51(6):843-856.

PMID: 38819494 DOI: 10.1007/s10488-024-01390-2.

Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-Occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study.

Chiappini S, Cavallotto C, Mosca A, Di Carlo F, Piro T, Giovannetti G Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675495 PMC: 11053971. DOI: 10.3390/ph17040535.

Presenting Pattern and Psychiatric Comorbidities in Rural versus Urban Substance Dependent Patients: A Hospital-Based Cross-Sectional Study.

Bansal P, Saini B, Bansal P, Bansal A, Dhillon J, Kaur V Indian J Community Med. 2023; 48(5):666-675.

PMID: 37970168 PMC: 10637592. DOI: 10.4103/ijcm.ijcm_618_22.

Efficacy of Psychosocial and Psychological Interventions in Addition to Drug Therapy to Improve Global Functioning of Inpatients with Schizophrenia Spectrum and Mood Disorders: A Real-World Observational Study.

Chiappini S, Di Carlo F, Mosca A, dAndrea G, Di Paolo M, Lorenzini C Neuropsychiatr Dis Treat. 2023; 19:1887-1897.

PMID: 37667738 PMC: 10475300. DOI: 10.2147/NDT.S418627.

References

Guerrero E, Padwa H, Lengnick-Hall R, Kong Y, Perrigo J . Leadership and Licensure for Drug Treatment and the Implementation of Co-Occurring Disorder Treatment in Community Mental Health Centers. Community Ment Health J. 2015; 51(5):554-66. PMC: 4476917. DOI: 10.1007/s10597-015-9886-0. View

Roncero C, Gomez-Baeza S, Vazquez J, Teran A, Szerman N, Casas M . Perception of Spanish professionals on therapeutic adherence of dual diagnosis patients. Actas Esp Psiquiatr. 2013; 41(6):319-29. View

Drake R, ONeal E, Wallach M . A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat. 2007; 34(1):123-38. DOI: 10.1016/j.jsat.2007.01.011. View

Garcia-Portilla M, Bobes-Bascaran M, Bascaran M, Saiz P, Bobes J . Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?. Br J Clin Pharmacol. 2012; 77(2):272-84. PMC: 4014027. DOI: 10.1111/bcp.12031. View

Monnat S, Rigg K . Examining Rural/Urban Differences in Prescription Opioid Misuse Among US Adolescents. J Rural Health. 2015; 32(2):204-18. PMC: 4779738. DOI: 10.1111/jrh.12141. View

King R . Science Over Stigma: Saving Lives--Implementation of Naloxone Use in the School Setting. NASN Sch Nurse. 2016; 31(2):96-101. DOI: 10.1177/1942602X16628890. View

Bizzarri J, Casetti V, Panzani P, Unterhauser J, Mulas S, Fanolla A . Risky use and misuse of alcohol and cigarettes in psychiatric inpatients: a screening questionnaire study. Compr Psychiatry. 2016; 70:9-16. DOI: 10.1016/j.comppsych.2016.05.011. View

Sterling S, Chi F, Hinman A . Integrating care for people with co-occurring alcohol and other drug, medical, and mental health conditions. Alcohol Res Health. 2013; 33(4):338-49. PMC: 3625993. View

Pani P, Trogu E, Vigna-Taglianti F, Mathis F, Diecidue R, Kirchmayer U . Psychopathological symptoms of patients with heroin addiction entering opioid agonist or therapeutic community treatment. Ann Gen Psychiatry. 2014; 13(1):35. PMC: 4247563. DOI: 10.1186/s12991-014-0035-x. View

10.

Bizzarri J, Rucci P, Sbrana A, Miniati M, Raimondi F, Ravani L . Substance use in severe mental illness: self-medication and vulnerability factors. Psychiatry Res. 2008; 165(1-2):88-95. DOI: 10.1016/j.psychres.2007.10.009. View

11.

Goswami S, Mattoo S, Basu D, Singh G . Substance-abusing schizophrenics: do they self-medicate?. Am J Addict. 2004; 13(2):139-50. DOI: 10.1080/10550490490435795. View

12.

Berenz E, Coffey S . Treatment of co-occurring posttraumatic stress disorder and substance use disorders. Curr Psychiatry Rep. 2012; 14(5):469-77. PMC: 3466083. DOI: 10.1007/s11920-012-0300-0. View

13.

Browne T, Priester M, Clone S, Iachini A, DeHart D, Hock R . Barriers and Facilitators to Substance Use Treatment in the Rural South: A Qualitative Study. J Rural Health. 2015; 32(1):92-101. DOI: 10.1111/jrh.12129. View

14.

Najt P, Fusar-Poli P, Brambilla P . Co-occurring mental and substance abuse disorders: a review on the potential predictors and clinical outcomes. Psychiatry Res. 2010; 186(2-3):159-64. DOI: 10.1016/j.psychres.2010.07.042. View

15.

Judd F, Jackson H, Komiti A, Murray G, Hodgins G, Fraser C . High prevalence disorders in urban and rural communities. Aust N Z J Psychiatry. 2002; 36(1):104-13. DOI: 10.1046/j.1440-1614.2002.00986.x. View

16.

Langas A, Malt U, Opjordsmoen S . In-depth study of personality disorders in first-admission patients with substance use disorders. BMC Psychiatry. 2012; 12:180. PMC: 3514215. DOI: 10.1186/1471-244X-12-180. View

17.

Green A . Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J Clin Psychiatry. 2005; 66 Suppl 6:21-6. View

18.

Brems C, Johnson M, Wells R, Burns R, Kletti N . Rates and sequelae of the coexistence of substance use and other psychiatric disorders. Int J Circumpolar Health. 2002; 61(3):224-44. DOI: 10.3402/ijch.v61i3.17456. View

19.

Milano G, Saenz E, Clark N, Busse A, Gale J, Campello G . Report on the International Workshop on Drug Prevention and Treatment in Rural Settings Organized by United Nation Office on Drugs and Crime (UNODC) and World Health Organization (WHO). Subst Use Misuse. 2017; 52(13):1801-1807. DOI: 10.1080/10826084.2017.1306564. View

20.

Mueser K, Essock S, Drake R, WOLFE R, Frisman L . Rural and urban differences in patients with a dual diagnosis. Schizophr Res. 2001; 48(1):93-107. DOI: 10.1016/s0920-9964(00)00065-7. View